What Polfilin prolongatum Treats: Main Uses and Benefits

The medication is applied in clinical settings that involve acute or unstable symptom patterns, when supportive symptom management is appropriate. Polfilin prolongatum is commonly used across conditions presenting with symptomatic manifestations that create noticeable functional strain.

Easing Symptomatic Burden and Functional Strain

Polfilin prolongatum is generally considered relevant for conditions characterized by periods of heightened symptoms or those presenting with episodic or fluctuating manifestations. It helps address symptom clusters that may become intense or disruptive, providing essential symptomatic support. The medicine is relevant for conditions associated with acute or disruptive episodes, commonly used for symptoms linked to organ-specific functional stress.

It assists with maintaining functional stability by addressing groups of symptoms that interfere with daily functioning, which ultimately contributes to improved comfort during symptomatic periods. By providing temporary assistance in symptom stabilization, it supports the patient during difficult episodes and helps ease the overall symptom burden associated with heightened discomfort.

---

Quick Fact: Supports general well-being during symptomatic phases

---

Regulatory References

1. Polish Government Medicine Register

Polfilin prolongatum, which contains pentoxifylline, is subject to specific eligibility rules documented in official regulatory sources.

Contraindications and Exclusions

The medicine is contraindicated and must not be used by individuals with a known hypersensitivity or intolerance to pentoxifylline or other methylxanthine derivatives (e.g., caffeine, theophylline). It is also prohibited for patients with a history of recent cerebral hemorrhage or extensive retinal hemorrhage. Some regulatory labels additionally contraindicate its use in patients with acute myocardial infarction or a recent history of peptic ulcers.

Use in Special Populations

Population	Eligibility Status (Regulatory)
Pediatric (Under 18)	Use not established; safety and efficacy are not confirmed.
Pregnancy	Not recommended; use only if potential benefit outweighs risk due to lack of adequate human data.
Lactation	Not recommended; drug and metabolites are excreted in human milk.
Severe Renal/Hepatic Impairment	Not recommended; requires careful monitoring and often dose reduction (for less severe impairment) due to drug accumulation risk.
Older Adults	Use with caution; potential for higher plasma levels necessitates dose adjustment.

Patients with conditions that increase the risk of bleeding or those with low or unstable blood pressure require special caution and close monitoring during treatment.

Polfilin prolongatum Interactions with other medicines and products

This section details officially documented interaction information for Polfilin prolongatum (pentoxifylline), based strictly on regulatory sources.

---

Documented Interaction Patterns

Polfilin prolongatum's active substance, pentoxifylline, can interact with other medications, potentially affecting their activity or altering plasma concentrations. These interactions are categorized as follows:

• Pharmacodynamic Potentiation

  • Anticoagulants (e.g., Vitamin K antagonists like warfarin) and Platelet Aggregation Inhibitors are associated with a documented risk of increased anticoagulant activity and reports of bleeding or prolonged prothrombin time. Regulatory labeling requires the monitoring of anticoagulant activity.
  • Antihypertensive Drugs may have their blood pressure-lowering effects enhanced, leading to small but documented decreases in blood pressure. Periodic systemic blood pressure monitoring is recommended.

• Exposure-Altering Interactions

  • Theophylline-containing Drugs: Co-administration leads to increased theophylline levels and a risk of toxicity. Close monitoring for signs of toxicity and dosage adjustment of theophylline are required.
  • Cimetidine and Strong CYP1A2 Inhibitors (e.g., ciprofloxacin, fluvoxamine) are documented to increase the plasma concentrations and overall exposure to pentoxifylline and its active metabolites.

---

Population and Combination Constraints

• Contraindications: Formal prohibitions exist for combinations with Ketorolac and in individuals with known intolerance to methylxanthines (e.g., caffeine, theophylline).
• Population Note: In patients with hepatic or renal impairment, an officially noted increase in drug exposure to pentoxifylline and/or its metabolites occurs, the clinical consequences of which are considered not known.

Mechanism of Action: Modulating Blood Flow and Cell Signaling

Polfilin prolongatum exerts its action primarily by inhibiting Phosphodiesterase (PDE) enzymes, specifically certain isoforms like PDE III and PDE IV. Blocking PDE prevents the breakdown of the second messengers cyclic adenosine monophosphate ( cAMP) and cyclic guanosine monophosphate ( cGMP), leading to their intracellular accumulation. This signaling modulation triggers smooth muscle relaxation in vessel walls, contributing to vasodilation and a modulation of microcirculatory flow.

Simultaneously, the drug acts by modifying hemorheological properties of the blood. It increases the deformability of erythrocytes (red blood cells) and leukocytes (white blood cells) and reduces their tendency toward aggregation. This mechanism leads to a reduction in blood viscosity, facilitating blood cell movement through the microvasculature. Furthermore, the drug modulates inflammatory processes by decreasing the release of pro-inflammatory cytokines (e.g., TNF-alpha) and reducing leukocyte adhesion to the vessel endothelium.

The administration of Polfilin prolongatum (pentoxifylline 400 mg prolonged-release tablets) follows specific protocols to ensure consistent delivery of the active substance.

Administration Scope

The medicine is designed for oral administration as an extended-release tablet. The tablets must be swallowed whole with a sufficient amount of liquid, and should not be crushed, broken, or chewed, as this compromises the prolonged-release properties.

Instruction	Detail
Standard Dosing Schedule	400 mg taken three times a day (TID), for a total of 1200 mg daily.
Dose Adjustment	If certain gastrointestinal effects occur, the dose may be reduced to 400 mg twice daily (800 mg/day) for maintenance or tolerability.
Timing in Relation to Meals	The tablets must be taken with or immediately after meals to minimize potential stomach upset.
Course Duration	While effects may appear in 2 to 4 weeks, treatment is recommended to continue for a minimum of 8 weeks to adequately assess the therapeutic response.

Population-Specific Use

Dose adjustment is recommended for specific patient populations. For patients with severe renal impairment (creatinine clearance below 30 mL/min), the dose should be reduced, often to 400 mg once a day. Similarly, a dose reduction may be required for those with severely impaired liver function. The medicine is not recommended for the pediatric population due to a lack of established safety and efficacy data.

Research evidence / Overview of studies for Polfilin prolongatum

This overview summarizes the available research describing the clinical evaluation of Polfilin prolongatum (pentoxifylline), based on findings from official scientific reviews and trials.

---

Evidence for Use in Chronic Peripheral Arterial Disease (PAD) with Intermittent Claudication

Research exploring the use of this medicine for chronic peripheral arterial disease has focused on patients with intermittent claudication, a condition that involves outcomes related to physical discomfort brought on by walking. The evidence base consists mainly of Randomized Controlled Trials (RCTs) and scientific reviews. These trials were conducted in adults and were designed to assess whether changes in functional capacity could be measured over defined time intervals, most often for periods ranging from 3 to 6 months.

Findings were often mixed across the studies, and the wide variability between individual trials has resulted in challenges when combining data for analysis. Scientific reviews have consistently noted that the certainty remains low for the measured outcomes related to walking distance. A key limitation is the variability of evidence quality and modest sample sizes across many older trials, which is associated with the generally low certainty of findings for this indication.

---

Evidence for Use as Adjunctive Treatment for Symptomatic Chronic Venous Leg Ulcers

Research for chronic venous leg ulcers (VLU) has focused on Randomized Controlled Trials and systematic reviews, where studies monitored the medicine's role when studied alongside standard compression therapy. The research examined outcomes related to physiological strain, with the main focus being on objective measures of Wound Healing.

Studies monitored specific outcomes such as the rate of complete ulcer healing and the time elapsed until healing was achieved. The evidence so far describes patterns where, when the medicine was studied alongside compression therapy, a higher number of participants achieved complete ulcer healing compared to the group using compression alone. This evidence is generally characterized as having moderate certainty in official reviews. A primary research gap is the limited information available concerning ulcer recurrence rates and evidence for subgroups that may have severe underlying conditions.

Key Studies & References Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials (1996)

Common questions about Polfilin prolongatum (FAQ)

Q: What is the difference between Polfilin and Polfilin prolongatum?

A: The designation prolongatum indicates that the medicine is formulated as a specialized extended-release tablet. This design is engineered to sustain the release of the active substance over a longer period compared to a standard formulation.

Q: What type of conditions is Polfilin prolongatum usually prescribed for?

A: According to official product information, the medicine is approved for the symptomatic treatment of claudication. Claudication is the leg pain and discomfort that is caused by chronic peripheral arterial disease (PAD).

Q: Does this medicine help with blood circulation issues in the legs?

A: Yes, the general purpose of Polfilin prolongatum is to improve microcirculatory function. The medicine is intended to be used for symptoms related to poor blood circulation in the lower extremities, which may help to reduce associated pain and discomfort.

Q: How long does it usually take to notice any effects from Polfilin prolongatum?

A: According to official product information, the full clinical effect of the medication typically requires a period of 2 to 4 weeks of continued therapy before any change may be noted.

Q: Is Polfilin prolongatum meant for long-term use, or only temporary?

A: The medication is often used as a long-term treatment. Official documents indicate that continued therapy for several weeks to months is necessary to fully assess its therapeutic response.

Q: What if I forget to take a dose of Polfilin prolongatum?

A: Official information states that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Double doses should not be taken to make up for a missed one.

Q: What happens if I accidentally take two tablets at once?

A: Taking more than the prescribed amount may lead to signs of overdose. These reported symptoms can include flushing, fainting, seizures, or severe drowsiness, and it is important to seek immediate medical attention if these occur.

Q: Does Polfilin prolongatum cause weight gain or changes in appetite?

A: Official regulatory safety reporting has included weight change as a miscellaneous adverse reaction. This means it has occurred in some patients but is not typically listed as a common side effect.

Q: Why does Polfilin prolongatum sometimes cause an upset stomach or nausea?

A: Nausea and upset stomach are common documented side effects. Official instructions state that the tablets should be taken with or immediately after meals to help minimize potential gastrointestinal irritation.

Q: Is a rash or persistent itching a serious side effect of Polfilin prolongatum?

A: A rash or persistent itching is listed as an uncommon side effect in official reports. However, these symptoms may also be signs of a serious, systemic allergic reaction (hypersensitivity), and it is important to seek immediate medical attention if these occur.

Q: Does this medication affect my blood pressure readings?

A: Regulatory safety documents describe a potential for low blood pressure (hypotension). This effect is documented as a rare adverse reaction of the medicine.

Q: Can Polfilin prolongatum cause insomnia or difficulties with sleep?

A: Yes, insomnia (difficulty sleeping) is listed in official documentation. It is reported as a nervous system side effect that has occurred in some patients using the medication.

Q: What are the common signs of a possible allergic reaction to Polfilin prolongatum?

A: Signs of a serious allergic reaction that indicate a need for emergency medical help are described in official safety documents. These typically include hives, swelling (of the face, lips, tongue, or throat), or difficulty breathing.

Q: Does Polfilin prolongatum interact with consuming caffeine?

A: The medicine is contraindicated in individuals with a known intolerance to methylxanthines. This chemical class includes both caffeine and theophylline, connecting the drug's safety profile to these substances.

Q: Is Polfilin prolongatum safe to take with common over-the-counter pain relievers like ibuprofen?

A: Caution is advised when the medicine is taken with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. This is due to a documented risk of increased bleeding or a prolonged prothrombin time.

Q: Can patients with diabetes safely use Polfilin prolongatum?

A: Clinical studies have examined the use of the medicine in patients with type 2 diabetes and related diabetic kidney issues. Official information suggests its use in this population may require monitoring.

Q: Does Polfilin prolongatum interfere with blood sugar medication or insulin?

A: Yes, clinical studies have indicated that the medicine may cause reductions in fasting plasma glucose and glycated hemoglobin. This suggests a potential effect on blood sugar control.

Q: Are there any known interactions between Polfilin prolongatum and common herbal supplements like ginkgo biloba?

A: Regulatory caution is noted for supplements such as ginkgo biloba that may interfere with blood clotting. This is due to the drug's own effect on blood properties, which could increase the risk of bleeding.

Q: Can I use Polfilin prolongatum if I have existing kidney problems?

A: Official guidelines indicate that use by patients with kidney problems requires caution and monitoring. For patients with severe kidney impairment, a dose reduction is generally required to avoid the risk of drug accumulation in the body.

Q: Is Polfilin prolongatum suitable for use in elderly patients?

A: Use in older adults requires caution according to official documentation. Elderly patients may be more sensitive to the effects of the medication, which may necessitate a lower or adjusted dose.

Q: Is this drug suitable for someone with a history of serious heart issues?

A: Regulatory documents state the medicine is contraindicated (prohibited) for individuals who have recently experienced an acute myocardial infarction or who present with certain severe heart rhythm issues.

Q: Why is Polfilin prolongatum not recommended for people with recent bleeding or stomach ulcers?

A: This restriction is based on the drug's effect on blood flow properties. Official information indicates that the medicine is associated with a documented risk of bleeding events (such as hemorrhage), which is why caution is needed for those with recent or active bleeding.

Q: How much research evidence is there to support the use of Polfilin prolongatum for its primary conditions?

A: Scientific reviews summarize the evidence base for the medicine. They have found low certainty evidence supporting its use for intermittent claudication and moderate certainty evidence when used alongside compression therapy for chronic venous leg ulcers.

How to Store and Dispose of Polfilin prolongatum?

The storage and disposal of Polfilin prolongatum must adhere strictly to official regulatory guidelines to maintain the stability of the prolonged-release tablet and ensure environmental safety.

Official Storage Requirements

Condition	Requirement
Temperature	Store below 25 C (Controlled Room Temperature).
Protection	Keep in the original package, protected from light and moisture.
Avoidance	Do not subject the tablets to freezing or excessive heat.
Child Safety	Keep out of the sight and reach of children.

Stability and Disposal

The product maintains a shelf-life of 3 years when stored correctly in its original, unopened container. When disposing of unused or expired medicine, it must not be discarded into household trash or down the wastewater/sewer system. Instead, return the product to a pharmacy or authorized local collection point to ensure environmentally responsible disposal.